Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xixiai HPV egg yolk antibody gynecological gel is a topical biologic product containing Immunoglobulin Y (IgY) extracted from the yolks of eggs laid by hens immunized against Human Papillomavirus (HPV). As a form of passive immunotherapy, the IgY antibodies are designed to specifically bind and neutralize HPV virions (typically targeting the L1 capsid protein) within the vaginal and cervical environment. This action prevents the virus from entering host epithelial cells, thereby inhibiting viral replication and promoting the clearance of persistent HPV infections. The gel is primarily utilized as an adjuvant therapy in women who have undergone cervical conization for high-grade squamous intraepithelial lesions (HSIL) to facilitate HPV DNA conversion to negative and reduce the risk of disease recurrence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-HPV egg yolk immunoglobulin.